Allogeneic Stem Cell Transplantation Market Size is valued at USD 3.66 Bn in 2022 and is predicted to reach USD 6.75 Bn by the year 2031 at a 7.21% CAGR during the forecast period for 2023-2031.
Key Industry Insights & Findings from the Report:
Allogeneic stem cell transplantation, also known as allogeneic hematopoietic stem cell transplantation (HSCT), refers to transferring the significant stem cells from a healthy donor to a desired patient. The donor can either be a biological relative, typically a sibling, or an unrelated individual whose tissue type is compatible with the recipient's. HLA matching can prevent graft rejection, graft-versus-host disease (GvHD), and other complications. Stem cells are exist in both the bone marrow and the blood. Hematopoietic stem cells are nascent or undeveloped blood cells within the bone marrow. Blood cells undergo maturation in the bone marrow, but only a minuscule portion of them enter the bloodstream. The cells that enter the bloodstream are referred to as peripheral blood stem cells. Moreover, the integration of allogeneic stem cells with biomaterials to generate bioengineered tissues and organs presents innovative possibilities for addressing severe diseases and injuries. The following are the latest trends in the allogeneic stem cell industry that are driving its growth.
In Addition, the market growth is impaded by the strict regulatory criteria for the safety and health of allogeneic stem cell transplantation and the product's inability to prevent fog in environments with dramatic temperature fluctuations or high humidity allogeneic stem cell transplantation, although regulatory rules are changing to facilitate the commercialization of cell therapies, rigorous evaluation is still required because of the lack of clarity regarding their long-term safety and effectiveness. Manufacturers must adhere to stringent restrictions from procuring stem cells via good tissue practices, cGMP standards, quality checks, and required preclinical research. To halt the spread of COVID-19, many nations have instituted nationwide lockdowns. Companies in the healthcare industry across the globe faced similar challenges when trying to keep their supply chains running smoothly. Since the frequency of new instances of COVID-19 decreased, limitations on patients visiting hospitals to receive treatment were relaxed.
The allogeneic stem cell transplantation market is segmented based on source, application, end user and cell type. According to source segment, the market is segmented into bone marrow, peripheral blood, umbilical cord blood, adipose tissue, dental pulp, and others. The application segment is segmented into cancer, autoimmune diseases, blood disorders, cardiac disorders, neurological disorders, diabetes, and others. By end user, the market is segmented into hospitals, research institutes, speciality clinics, and others. By cell type, the market is segmented into allogeneic MSCs, allogeneic HSCs, and others.
The bone marrow allogeneic stem cell transplantation market is expected to lead with a major global market share in 2022. Bone marrow stem cell transplantation has shown promise as a potential cure for some haematological diseases, especially when standard treatments have failed or the disease has returned. For individuals who are candidates, this treatment is crucial since it can prolong life for years without relapse.
The hospital industry makes up the bulk of allogeneic stem cell transplantation because, in modern hospitals, patients have access to state-of-the-art medical technology, including bone marrow transplantation units. These resources allow hospitals to provide comprehensive pre-and post-transplant care for HSCT recipients, especially in countries like the US, Germany, the UK, China, and India.
The North American allogeneic stem cell transplantation market is expected to record the maximum market share in revenue in the near future. It can be attributed to the high acceptance of stem cell therapies, improved healthcare infrastructure, and increasing R&D investments fueling the market's expansion. In addition, Asia Pacific is estimated to grow rapidly in the global allogeneic stem cell transplantation market because of the large population and increasing demand for high-quality healthcare in the region, as well as the growing number of people who are becoming more health-conscious and in need of cutting-edge medical technology for skin care.
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 3.66 Bn |
|
Revenue Forecast In 2031 |
USD 6.75 Bn |
|
Growth Rate CAGR |
CAGR of 7.21% from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Bn and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Source, Application, Cell Type, End-User |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; France; Italy; Spain; South East Asia; South Korea |
|
Competitive Landscape |
Celgene Corporation, Mesoblast Ltd., Pluristem Therapeutics Inc., MEDIPOST Co., Ltd., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Cellular Biomedicine Group, Inc., Biosolution Co., Ltd., StemCell Technologies Inc., Caladrius Biosciences, Inc., TiGenix N.V., ViaCord, Vericel Corporation, Regen Biopharma Inc., Gamida Cell Ltd., Histogenics Corporation, BrainStorm Cell Therapeutics Inc., Lineage Cell Therapeutics, Inc., Bluebird Bio, Sanofi, Talaris Therapeutics and Others |
|
Customization Scope |
Free customization report with the procurement of the report and modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
Chapter 1. Methodology and Scope
1.1. Research Methodology
1.2. Research Scope & Assumptions
Chapter 2. Executive Summary
Chapter 3. Global Allogeneic Stem Cell Transplantation Market Snapshot
Chapter 4. Global Allogeneic Stem Cell Transplantation Market Variables, Trends & Scope
4.1. Market Segmentation & Scope
4.2. Drivers
4.3. Challenges
4.4. Trends
4.5. Investment and Funding Analysis
4.6. Industry Analysis – Porter’s Five Forces Analysis
4.7. Competitive Landscape & Market Share Analysis
4.8. Impact of Covid-19 Analysis
Chapter 5. Market Segmentation 1: By Source Estimates & Trend Analysis
5.1. By Source, & Market Share, 2020 & 2031
5.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Source:
5.2.1. Bone Marrow
5.2.2. Peripheral Blood
5.2.3. Umbilical Cord Blood
5.2.4. Adipose Tissue
5.2.5. Dental Pulp
5.2.6. Others
Chapter 6. Market Segmentation 2: By Application Estimates & Trend Analysis
6.1. By Application & Market Share, 2020 & 2031
6.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Application:
6.2.1. Cancer
6.2.2. Autoimmune Diseases
6.2.3. Blood Disorder
6.2.4. Cardiac Disorders
6.2.5. Neurological Disorders
6.2.6. Diabetes
6.2.7. Others
Chapter 7. Market Segmentation 3: By Cell Type Estimates & Trend Analysis
7.1. By Cell Type & Market Share, 2020 & 2031
7.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By Cell Type:
7.2.1. Allogeneic MSCs
7.2.2. Allogeneic HSCs
7.2.3. Others
Chapter 8. Market Segmentation 4: By End User Estimates & Trend Analysis
8.1. By End User & Market Share, 2020 & 2031
8.2. Market Size (Value US$ Mn) & Forecasts and Trend Analyses, 2020 to 2031 for the following By End User:
8.2.1. Hospitals
8.2.2. Research Institutes
8.2.3. Specialty Clinics
8.2.4. Others
Chapter 9. Allogeneic Stem Cell Transplantation Market Segmentation 5: Regional Estimates & Trend Analysis
9.1. North America
9.1.1. North America Allogeneic Stem Cell Transplantation Market revenue (US$ Million) estimates and forecasts By Source, 2019-2031
9.1.2. North America Allogeneic Stem Cell Transplantation Market revenue (US$ Million) estimates and forecasts By Application, 2019-2031
9.1.3. North America Allogeneic Stem Cell Transplantation Market revenue (US$ Million) estimates and forecasts By Cell Type, 2019-2031
9.1.4. North America Allogeneic Stem Cell Transplantation Market revenue (US$ Million) estimates and forecasts By End User, 2019-2031
9.1.5. North America Allogeneic Stem Cell Transplantation Market revenue (US$ Million) estimates and forecasts by country, 2019-2031
9.2. Europe
9.2.1. Europe Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Source, 2019-2031
9.2.2. Europe Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Application, 2019-2031
9.2.3. Europe Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Cell Type, 2019-2031
9.2.4. Europe Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By End User, 2019-2031
9.2.5. Europe Allogeneic Stem Cell Transplantation Market revenue (US$ Million) by country, 2019-2031
9.3. Asia Pacific
9.3.1. Asia Pacific Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Source, 2019-2031
9.3.2. Asia Pacific Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Application, 2019-2031
9.3.3. Asia Pacific Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Cell Type, 2019-2031
9.3.4. Asia Pacific Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By End User, 2019-2031
9.3.5. Asia Pacific Allogeneic Stem Cell Transplantation Market revenue (US$ Million) by country, 2019-2031
9.4. Latin America
9.4.1. Latin America Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Source, (US$ Million) 2019-2031
9.4.2. Latin America Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
9.4.3. Latin America Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Cell Type, (US$ Million) 2019-2031
9.4.4. Latin America Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By End User, (US$ Million) 2019-2031
9.4.5. Latin America Allogeneic Stem Cell Transplantation Market revenue (US$ Million) by country, 2019-2031
9.5. Middle East & Africa
9.5.1. Middle East & Africa Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Source, (US$ Million) 2019-2031
9.5.2. Middle East & Africa Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Application, (US$ Million) 2019-2031
9.5.3. Middle East & Africa Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By Cell Type, (US$ Million) 2019-2031
9.5.4. Middle East & Africa Allogeneic Stem Cell Transplantation Market revenue (US$ Million) By End User, (US$ Million) 2019-2031
9.5.5. Middle East & Africa Allogeneic Stem Cell Transplantation Market revenue (US$ Million) by country, 2019-2031
Chapter 10. Competitive Landscape
10.1. Major Mergers and Acquisitions/Strategic Alliances
10.2. Company Profiles
10.2.1. Celgene Corporation,
10.2.2. Mesoblast Ltd.,
10.2.3. Pluristem Therapeutics Inc.,
10.2.4. MEDIPOST Co., Ltd.,
10.2.5. Takeda Pharmaceutical Company Limited,
10.2.6. Astellas Pharma Inc.,
10.2.7. Cellular Biomedicine Group, Inc.,
10.2.8. Biosolution Co., Ltd.,
10.2.9. StemCell Technologies Inc.,
10.2.10. Caladrius Biosciences, Inc.,
10.2.11. TiGenix N.V.,
10.2.12. ViaCord,
10.2.13. Vericel Corporation,
10.2.14. Regen Biopharma Inc.,
10.2.15. Gamida Cell Ltd.,
10.2.16. Histogenics Corporation,
10.2.17. BrainStorm Cell Therapeutics Inc.,
10.2.18. Lineage Cell Therapeutics, Inc.
Allogeneic Stem Cell Transplantation Market By Source
Allogeneic Stem Cell Transplantation Market By Cell Type
Allogeneic Stem Cell Transplantation Market By Application
Allogeneic Stem Cell Transplantation Market By End User
Allogeneic Stem Cell Transplantation Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
InsightAce Analytic follows a standard and comprehensive market research methodology focused on offering the most accurate and precise market insights. The methods followed for all our market research studies include three significant steps – primary research, secondary research, and data modeling and analysis - to derive the current market size and forecast it over the forecast period. In this study, these three steps were used iteratively to generate valid data points (minimum deviation), which were cross-validated through multiple approaches mentioned below in the data modeling section.
Through secondary research methods, information on the market under study, its peer, and the parent market was collected. This information was then entered into data models. The resulted data points and insights were then validated by primary participants.
Based on additional insights from these primary participants, more directional efforts were put into doing secondary research and optimize data models. This process was repeated till all data models used in the study produced similar results (with minimum deviation). This way, this iterative process was able to generate the most accurate market numbers and qualitative insights.
Secondary research
The secondary research sources that are typically mentioned to include, but are not limited to:
The paid sources for secondary research like Factiva, OneSource, Hoovers, and Statista
Primary Research:
Primary research involves telephonic interviews, e-mail interactions, as well as face-to-face interviews for each market, category, segment, and subsegment across geographies
The contributors who typically take part in such a course include, but are not limited to:
Data Modeling and Analysis:
In the iterative process (mentioned above), data models received inputs from primary as well as secondary sources. But analysts working on these models were the key. They used their extensive knowledge and experience about industry and topic to make changes and fine-tuning these models as per the product/service under study.
The standard data models used while studying this market were the top-down and bottom-up approaches and the company shares analysis model. However, other methods were also used along with these – which were specific to the industry and product/service under study.
To know more about the research methodology used for this study, kindly contact us/click here.
